Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza

Clicks: 1
ID: 307133
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #450 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Coronavirus disease 2019 (COVID-19) is an emerging serious global health problem. Gastrointestinal symptoms are common in COVID-19 patients, and severe acute respiratory syndrome coronavirus 2 RNA has been detected in stool specimens. However, the relationship between the gut microbiome and disease remains to be established. Methods We conducted a cross-sectional study of 30 patients with COVID-19, 24 patients with influenza A(H1N1), and 30 matched healthy controls (HCs) to identify differences in the gut microbiota by 16S ribosomal RNA gene V3–V4 region sequencing. Results Compared with HCs, COVID-19 patients had significantly reduced bacterial diversity; a significantly higher relative abundance of opportunistic pathogens, such as Streptococcus, Rothia, Veillonella, and Actinomyces; and a lower relative abundance of beneficial symbionts. Five biomarkers showed high accuracy for distinguishing COVID-19 patients from HCs with an area under the curve (AUC) up to 0.89. Patients with H1N1 displayed lower diversity and different overall microbial composition compared with COVID-19 patients. Seven biomarkers were selected to distinguish the 2 cohorts (AUC = 0.94). Conclusions The gut microbial signature of patients with COVID-19 was different from that of H1N1 patients and HCs. Our study suggests the potential value of the gut microbiota as a diagnostic biomarker and therapeutic target for COVID-19, but further validation is needed.
Reference Key
openalex_W3033735761 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Silan Gu, Yanfei Chen, Zhengjie Wu, Yunbo Chen, Hainv Gao, Longxian Lv, Feifei Guo, Xuewu Zhang, Rui Luo, Chenjie Huang, Haifeng Lu, Beiwen Zheng, Jiaying Zhang, Yan Ren, Hua Zhang, Huiyong Jiang, Qiaomai Xu, Jing Guo, Yiwen Gong, Lingling Tang, Lanjuan Li
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2020
DOI
10.1093/cid/ciaa709
URL
https://academic.oup.com/cid/article-pdf/71/10/2669/34932943/ciaa709.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.